Small molecule anticancer agents
The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
1. A compound of Formula I, or salt thereof:
wherein,
each X is independently S or Se;
each Y is independently S or Se;
each Z is independently S or Se;
each Z 1 , Z 2 , and Z 3 is independently
and
each R 7 is independently H, Na, K, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl.
2. A compound of Formula II, or salt thereof:
wherein,
each X is independently S or Se;
each Y is independently S or Se;
each Z is independently S or Se;
each Z 1 , Z 2 , Z 3 , and Z 4 is independently
each R 7 is independently H, Na, K, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and
each n is independently 0, 1, 2 or 3.
3. The compound of claim 1 , or salt thereof:
wherein, X is S; Y is S; and Z is S.
4. The compound of claim 1 , or salt thereof, wherein, X is S; Y is S; Z is S; and R 7 is K or Na.
5. The compound of claim 2 , or salt thereof, wherein, n is 1; X is S; Y is S; Z is S; and R 7 is K or Na.
6. A compound that is:
or salt thereof.
7. A method of treating a subject suffering from cancer comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a salt thereof.
8. The method of claim 7 , wherein the cancer is HER2 mediated or breast cancer.
9. The method of claim 8 , wherein the breast cancer is HER2-positive breast cancer.
10. The method of claim 8 , wherein the breast cancer is mediated by HER2, HER3, and/or EGFR.
11. A method of inhibiting cancer cell proliferation comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a salt thereof.
12. The method of claim 11 , wherein the cancer cell is HER2 mediated or a breast cancer cell.
13. The method of claim 12 , wherein the breast cancer cell is a HER2-positive breast cancer cell.
14. A method of inhibiting cancer cell metastasis comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a salt thereof.
15. A kit for treating a cell proliferative disorder, the kit comprising a compound of claim 1 , or a salt thereof, and instructions for use.
16. A pharmaceutical composition comprising a compound of claim 1 , or a salt thereof, and a pharmaceutically acceptable carrier.
17. The composition of claim 16 , further comprising an additional therapeutic agent.
18. The composition of claim 17 , wherein the additional therapeutic agent is lapatinib or trastuzumab.
19. A method of treating a subject suffering from cancer comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 2 , or a salt thereof.
20. A method of inhibiting cancer cell proliferation comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 2 , or a salt thereof.